https://clinicaltrials.gov/ct2/show/NCT02698475?type=Intr&cond=Psoriasis&lupd_s=03%2F14%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Ustekinumab 0.75 mg/kg; Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg
Sponsor : Janssen Research & Development, LLC
Active, not recruiting
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475
Thu, 03 Mar 2016 12:00:00 EST
Last Update Posted: 03/28/19 09:26AM